AVROBIO is a clinical-stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Co.'s initial focus is on a group of rare genetic diseases referred to as lysosomal disorders, some of which are mainly managed with enzyme replacement therapies. Co.'s pipeline consists of five lentiviral-based gene therapy programs: AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease. The AVRO stock yearly return is shown above.
The yearly return on the AVRO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AVRO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|